Werewolf Therapeutics Inc (HOWL) Stock Price, Quote & News

Company Profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activa...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 952 0555

Website: werewolftx.com

Address:

200 Talcott Ave, 2nd Floor, Watertown, United States

anachartanalyst Aug. 21 at 2:02 PM

$HOWL https://anachart.com/wp-content/uploads/ana_temp/1755784903_soc-img.jpg

0 · Reply

JarvisFlow Aug. 21 at 1:12 PM

JMP Securities has adjusted their stance on Werewolf Therapeutics ( $HOWL ), setting the rating to Market Outperform with a target price of 4 → 3.

0 · Reply

Train1980 Aug. 15 at 6:15 PM

$HOWL $WDC I agree HOWL is a big risk, but with this price and catalyst expected next quarter it could be worth the risk at least for the short term IMO

1 · Reply

d_risk Aug. 14 at 4:18 PM

$WDC $HOWL - Werewolf Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors HOWL’s latest 10-Q expands on early-stage biopharma risks: limited operating history, unproven platform, heavy reliance on just two lead candidates, major funding needs, new loan covenants, tax law uncertainty, granular clinical and IP hurdles, manufacturing and commercialization challenges, and heightened risks from stock volatility, Nasdaq compliance, and streamlined cybersecurity disclosures. #Biopharmaceuticals #StockVolatility #ClinicalTrials #FundingChallenges #EarlyStageRisk 🟢 Added 🟠 Removed https://d-risk.ai/HOWL/10-Q/2025-08-14

0 · Reply

theBigDollarski Aug. 14 at 12:07 PM

$HOWL running out of runway...data better be good or they're toast

0 · Reply

Whirledpeas Aug. 13 at 10:41 PM

$HOWL

0 · Reply

longshot45 Aug. 11 at 7:42 PM

$HOWL Very low volume day.

0 · Reply

tommiemac Aug. 6 at 5:13 PM

$HOWL like lxrx

0 · Reply

the_real_Joker Aug. 5 at 10:16 AM

$PSTX 30% right now somehow there should be more.↑↑🤔And what about $HOWL, do they ever give any news?🐺

0 · Reply

Astars Aug. 1 at 11:05 PM

$HOWL gessssh 🙄 🚮. One day 🙏🏻

0 · Reply

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 9, 2025, 8:00 AM EDT - 6 weeks ago

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

Jun 12, 2025, 8:00 AM EDT - 2 months ago

Werewolf Therapeutics to Participate in the BIO International Convention

May 29, 2025, 8:00 AM EDT - 3 months ago

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

May 20, 2025, 4:01 PM EDT - 3 months ago

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

May 13, 2025, 8:00 AM EDT - 3 months ago

Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit

May 8, 2025, 7:00 AM EDT - 3 months ago

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:05 AM EDT - 3 months ago

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

May 5, 2025, 8:00 AM EDT - 3 months ago

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

Apr 17, 2025, 8:00 AM EDT - 4 months ago

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

Mar 31, 2025, 8:00 AM EDT - 5 months ago

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 11, 2025, 7:00 AM EDT - 5 months ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 4, 2025, 8:00 AM EST - 6 months ago

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

Feb 24, 2025, 7:30 AM EST - 6 months ago

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Jan 13, 2025, 8:00 AM EST - 7 months ago

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

Nov 20, 2024, 8:00 AM EST - 9 months ago

Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 7, 2024, 9:02 AM EST - 10 months ago

Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Oct 4, 2024, 9:00 AM EDT - 11 months ago

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 1, 2024, 10:04 AM EDT - 1 year ago

Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1

Jun 25, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

Jun 1, 2024, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

May 30, 2024, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference

May 23, 2024, 5:00 PM EDT - 1 year ago

Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting

May 3, 2024, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 24, 2024, 10:05 AM EDT - 1 year ago

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Apr 5, 2024, 4:30 PM EDT - 1 year ago

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

Apr 4, 2024, 4:57 PM EDT - 1 year ago

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 4, 2024, 4:30 PM EDT - 1 year ago

Werewolf Therapeutics to Present First-of-Its-Kind Data Demonstrating Utility for PREDATOR™ Platform in Immunology-Based Diseases at AAI Annual Meeting

Mar 7, 2024, 7:00 AM EST - 1 year ago

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 8:00 AM EST - 1 year ago

Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference

Mar 5, 2024, 4:30 PM EST - 1 year ago

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

Jan 8, 2024, 7:00 AM EST - 1 year ago

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

Jan 4, 2024, 4:05 PM EST - 1 year ago

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

Dec 28, 2023, 7:09 PM EST - 1 year ago

Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines

Nov 22, 2023, 7:00 AM EST - 1 year ago

Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference

Nov 14, 2023, 4:25 PM EST - 1 year ago

Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 5:14 PM EST - 1 year ago

Werewolf Therapeutics: Possibly A Transformative IL-2, But Still Early Days

Nov 3, 2023, 7:00 AM EDT - 1 year ago

Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 31, 2023, 9:00 AM EDT - 1 year ago

Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 11, 2023, 4:05 PM EDT - 2 years ago

Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124

Aug 25, 2023, 4:48 PM EDT - 2 years ago

Werewolf: Q4 2023 Data Readout And Enhancement Of Validated Targets

Aug 10, 2023, 7:10 AM EDT - 2 years ago

Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Jun 1, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics to Present at the Jefferies Healthcare Conference

May 11, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 1, 2023, 7:00 AM EDT - 2 years ago

Werewolf Therapeutics to Participate in May Investor Conferences

Apr 28, 2023, 3:30 PM EDT - 2 years ago

Werewolf Therapeutics: A Clinical Stage Biotech On The Hunt For Results In 2023

Apr 19, 2023, 10:00 AM EDT - 2 years ago

Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research

anachartanalyst Aug. 21 at 2:02 PM

$HOWL https://anachart.com/wp-content/uploads/ana_temp/1755784903_soc-img.jpg

0 · Reply

JarvisFlow Aug. 21 at 1:12 PM

JMP Securities has adjusted their stance on Werewolf Therapeutics ( $HOWL ), setting the rating to Market Outperform with a target price of 4 → 3.

0 · Reply

Train1980 Aug. 15 at 6:15 PM

$HOWL $WDC I agree HOWL is a big risk, but with this price and catalyst expected next quarter it could be worth the risk at least for the short term IMO

1 · Reply

d_risk Aug. 14 at 4:18 PM

0 · Reply

theBigDollarski Aug. 14 at 12:07 PM

$HOWL running out of runway...data better be good or they're toast

0 · Reply

Whirledpeas Aug. 13 at 10:41 PM

$HOWL

0 · Reply

longshot45 Aug. 11 at 7:42 PM

$HOWL Very low volume day.

0 · Reply

tommiemac Aug. 6 at 5:13 PM

$HOWL like lxrx

0 · Reply

the_real_Joker Aug. 5 at 10:16 AM

$PSTX 30% right now somehow there should be more.↑↑🤔And what about $HOWL, do they ever give any news?🐺

0 · Reply

Astars Aug. 1 at 11:05 PM

$HOWL gessssh 🙄 🚮. One day 🙏🏻

0 · Reply

the_real_Joker Jul. 24 at 5:34 PM

$HOWL what the hell was that just now?

1 · Reply

the_real_Joker Jul. 24 at 12:58 PM

$HOWL Every day at opening I have to howl here.💤💤

0 · Reply

Smittysixty Jul. 21 at 4:11 PM

When you see $PPBT thrown into lists alongside $ALXO $JANX $CUE $HOWL, that’s not analysis—it’s camouflage. It’s a tactic to normalize the price rise by anchoring it to other names with far earlier pipelines, higher burn rates, and limited data. 💥 Purple Biotech stands alone: • Phase 2 survival data in pancreatic cancer shows up to 90% death risk reduction in biomarker-selected patients. • CAPTN-3 platform is a tri-specific antibody engaging both T cells and NK cells. Solid tumor innovation with dual immune activation. • Cash runway to 2026, focused pipeline, expanding IP, and a strategy that’s quietly creating asymmetrical upside. These drugs remains grossly undervalued vs. peers still in Phase 1 or chasing crowded targets. Don’t let ticker bundling blur the signal. This biotech isn’t rising with the tide—it’s cutting through it. 🧬👊

1 · Reply

the_real_Joker Jul. 21 at 2:09 PM

$HOWL ← need to buy more.. b4 news expects..↑↑↑🤓 $IXHL i'm out because little afraid about insta dillution moves after the allready priced results. I don't expect a take over, then they need some bucks for the further pipeline and NASDAQ rules compliance. Daytrader's and shorters now on the plan.. i hate there actions.

3 · Reply

ThisWi11hurt Jul. 21 at 1:46 PM

$PPBT keeping it real I don’t get too into the nitty gritty of the methods of action etc. but Grok tells me PPBT is in the same class as $ALXO $JANX $CUE $HOWL. All of these stocks, PPBT included are drifting up ready for breakouts. Cancer funding announcements are about to come out I can feel it

1 · Reply

LabPsycho Jul. 20 at 8:53 PM

$HOWL @ibaian Looks like cost basis for the one's I've skimmed over - $0, ergo probably part of pay compensation. https://investors.werewolftx.com/financial-information/sec-filings

0 · Reply

ibaian Jul. 19 at 1:03 AM

$HOWL 92 million cash $$ available, only 26 % share avialable for PUBLIC, rest with institutions and insiderss

0 · Reply

ibaian Jul. 18 at 5:25 PM

$HOWL insider bought 536,426 shares during last 3 months

0 · Reply

greatnez Jul. 18 at 4:07 PM

$HOWL No FDA approval today?

0 · Reply

RG_trades Jul. 18 at 5:27 AM

$HOWL fda approval tomorrow?

1 · Reply

uconnbball2022 Jul. 17 at 7:11 PM

0 · Reply

LabPsycho Jul. 17 at 2:12 PM

$HOWL Now the low trade float up to $1.50 soon? see below. The several trade days of big volume no significant price move about a week ago was a tip to me HOWL likely going higher

0 · Reply

Market Cap	60.36M
Revenue (ttm)	1.89M
Net Income (ttm)	-70.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,731.22%
Debt to Equity Ratio	0.60

Volume	114,900
Avg Vol	355,806
Day's Range	N/A - N/A
Shares Out	45.73M
Stochastic %K	66%
Beta	0.63
Analysts	Strong Sell
Price Target	$7.33